Shionogi In-licenses Shire ADHD Drugs In Untapped Japanese Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Severe disappointment in U.S. performance has Shionogi looking back home, where ADHD has high growth potential as well as high hurdles.